Observational studyBMC complementary and alternative medicine2017
A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study.
Observational study in BMC complementary and alternative medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02901756 (A Combination of Coenzyme Q10, Feverfew and Magnesium for Migraine Prophylaxis), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Combination of Coenzyme Q10, Feverfew and Magnesium for Migraine Prophylaxis : a Prospective Observational Study
Who cites it
21 citing papers in PubMed.
- The impact of alternate nostril breathing on the severity and frequency of migraine attacks: a randomized control trial.Primary health care research & development · 2025Trial
- Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms.Journal of clinical medicine · 2026Review
- Evaluating the Role of Coenzyme Q10 in Migraine Therapy-A Narrative Review.Antioxidants (Basel, Switzerland) · 2025Review
- Nutraceuticals and Headache 2024: Riboflavin, Coenzyme Q10, Feverfew, Magnesium, Melatonin, and Butterbur.Current pain and headache reports · 2025Review
- Bridging Gaps in Migraine Management: A Comprehensive Review of Conventional Treatments, Natural Supplements, Complementary Therapies, and Lifestyle Modifications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Energy metabolism disorders in migraine: triggers, pathways, and therapeutic repurposing.Frontiers in neurology · 2025Review
- Hallmarks of primary headache: part 1 - migraine.The journal of headache and pain · 2024Review
- Association between the Composite Dietary Antioxidant Index and severe headache or migraine: results from the National Health and Nutrition Examination Survey.Frontiers in neurology · 2024Article
- Integrative, Interventional, and Non-invasive Approaches for the Treatment for Migraine During Pregnancy.Current pain and headache reports · 2022Review
- Review on Headache Related to Dietary Supplements.Current pain and headache reports · 2022Review
- A Comparative Study on the Efficacy of Coenzyme Q10 and Amitriptyline in the Prophylactic Treatment of Migraine Headaches in Children: A Randomized Controlled Trial.Advanced biomedical research · 2022Article
- Coenzyme Q10 effects in neurological diseases.Physiological research · 2021Review
- Nutraceuticals and Behavioral Therapy for Headache.Current neurology and neuroscience reports · 2021Review
- The Efficacy of Herbal Supplements and Nutraceuticals for Prevention of Migraine: Can They Help?Cureus · 2021Review
- Open Label Prospective Experience of Supplementation with a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis.Journal of clinical medicine · 2020Article
- Anti-Inflammatory and Neuromodulatory Effects Induced byMolecules (Basel, Switzerland) · 2020Article
- The Use of Antioxidants in the Treatment of Migraine.Antioxidants (Basel, Switzerland) · 2020Review
- The Effect of CoQPsychology research and behavior management · 2020Article
- Complementary and Integrative Health Treatments for Migraine.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2019Review
- Complementary and Integrative Medicine for Episodic Migraine: an Update of Evidence from the Last 3 Years.Current pain and headache reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFeverfew (Tanacetum parthenium L.), magnesium and coenzyme Q10 are frequently used for migraine prophylaxis. Supplementation with a fixed combination of these three agents (Antemig®, PiLeJe) was investigated in an observational study.
methodsAdult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and medication overuse) and after a one-month baseline phase, supplemented with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months.
resultsSupplementation significantly reduced the number of days with migraine headache during third month of supplementation compared to baseline phase (1.3 days ±1.5 versus 4.9 days ±2.6, p < 0.0001; n = 68 intention to treat; primary criterion). The decrease was progressive over the period of supplementation and significant from first month (1st month: -2.5 days ±3.1, p < 0.0001; 2nd month: -3 days ±2.8, p < 0.0001). The proportion of patients with a reduction of at least 50% in the number of days with migraine headache was 75% (51/68) after 3 months, with a progressive increase over the period of supplementation (63.2% [43/68] after 1 month and 70.6% [48/68] after 2 months). The proportion of patients with anxiety and depressive symptoms (Hospital Anxiety and Depression Scale) decreased between baseline phase and third month of supplementation from 61.9% (39/63 patients with information available) to 35% (21/60) for depression and from 52.4% (33/63) to 30% (18/60) for anxiety. An improvement of quality of life (Qualité de Vie et Migraine questionnaire) was also observed. The combination was well tolerated.
conclusionsResults suggest that the proprietary supplement containing feverfew, coenzyme Q10 and magnesium assessed could be beneficial and safe for the prevention of migraine in adult patients and merits further study.
trial registrationClinicalTrials.gov: NCT02901756 , retrospectively registered on August 24, 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.